FIELD: medicine, pharmacy.
SUBSTANCE: invention proposes a medicinal formulation consisting of a core and the stomach-dissolving envelope. The core comprises trimetazidine dihydrochloride as an active component, and starch, mannitol, povidone, magnesium stearate, croscarmelose and microcrystalline cellulose as accessory substances. The envelope comprises hydroxypropylmethylcellulose, polyethylene glycol, titanium dioxide, magnesium stearate and acid red as a dye. Also, invention describes a method for making the trimetazidine medicinal formulation. Trimetazidine tablets show high mechanical strength in the low pressing strength (3.5-5 kH). The composition of the medicinal formulation provides releasing 80% of trimetazidine for 30 min.
EFFECT: improved and valuable properties of formulation.
3 cl, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MODIFIED RELEASE DOSAGE FORM OF TRIMETAZIDINE DIHYDROCHLORIDE | 2009 |
|
RU2412706C1 |
| MEDICINAL FORMULATION POSSESSING BACTERIOSTATIC EFFECT AND METHOD FOR ITS PREPARING | 2003 |
|
RU2268051C2 |
| PROLONGED PHARMACEUTICAL COMPOSITION DRUG FORM AND METHOD OF ITS PRODUCTION (VERSIONS) | 2009 |
|
RU2435584C2 |
| MEDICINAL FORMULATION POSSESSING ANTI-ANGINAL EFFECT AND METHOD FOR ITS PREPARING | 2005 |
|
RU2281772C1 |
| MEDICINAL FORMULATION POSSESSING ANTI-VOMITING EFFECT AND METHOD FOR ITS PREPARING | 2003 |
|
RU2268047C2 |
| PHARMACEUTICAL COMPOSITION EXHIBITING CARDIOVASCULAR EFFECT | 1999 |
|
RU2145214C1 |
| PHARMACEUTICAL AGENT WITH CARDIOVASCULAR EFFECT | 2001 |
|
RU2206316C1 |
| PHARMACEUTICAL COMPOSITION IN SOLID FORM WITH ANALGESIC ACTIVITY | 2013 |
|
RU2545861C1 |
| METHOD OF OBTAINING MEDICAL FORM OF TRIMETAZIDINE OF PROLONGED ACTION | 2012 |
|
RU2530558C2 |
| PHARMACEUTICAL COMPOSITION ELICITING ANTIVIRAL ACTIVITY AS SOLID DOSED FORMULATION AND METHOD FOR ITS PREPARING | 2003 |
|
RU2254860C2 |
